Tsukagoshi Mariko, Wada Satoshi, Yokobori Takehiko, Altan Bolag, Ishii Norihiro, Watanabe Akira, Kubo Norio, Saito Fumiyoshi, Araki Kenichiro, Suzuki Hideki, Hosouchi Yasuo, Kuwano Hiroyuki
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
Department of Cancer Immunotherapy, Kanagawa Cancer Center, Yokohama, Japan.
Cancer Sci. 2016 Feb;107(2):116-22. doi: 10.1111/cas.12853. Epub 2016 Feb 2.
The natural killer group 2 member D (NKG2D) receptor and its ligands are important mediators of immune responses to tumors. NKG2D ligands are overexpressed in several malignant tumor types; however, the prognostic value of these ligands is unclear. Here, we aimed to elucidate the role of NKG2D ligands in extrahepatic cholangiocarcinoma (EHCC). We therefore investigated the expression of the NKG2D receptor and its ligands MHC class I chain-related proteins A and B (MICA/B), unique long 16 binding protein (ULBP) 1, and ULBP2/5/6 in resected specimens from 82 patients with EHCC. All NKG2D ligands were highly expressed in EHCC. High expression of MICA/B or ULBP2/5/6 correlated with overall and disease-free survival. In contrast, high expression of ULBP1 was significantly associated with improved overall survival, but not disease-free survival. Concurrent high expression of multiple NKG2D ligands revealed significantly better overall and disease-free survival than that observed with the overexpression of any one NKG2D ligand. Co-expression of multiple NKG2D ligands was an independent prognostic indicator of improved survival. Furthermore, co-overexpression of multiple NKG2D ligands was significantly correlated with high expression of the NKG2D receptor. Inhibiting interactions between multiple NKG2D ligands and the NKG2D receptor might be a promising approach for controlling cancer progression and improving patient prognosis in EHCC.
自然杀伤细胞2成员D(NKG2D)受体及其配体是肿瘤免疫反应的重要介质。NKG2D配体在多种恶性肿瘤类型中过表达;然而,这些配体的预后价值尚不清楚。在此,我们旨在阐明NKG2D配体在肝外胆管癌(EHCC)中的作用。因此,我们研究了82例EHCC患者切除标本中NKG2D受体及其配体MHC I类链相关蛋白A和B(MICA/B)、独特长16结合蛋白(ULBP)1以及ULBP2/5/6的表达情况。所有NKG2D配体在EHCC中均高表达。MICA/B或ULBP2/5/6的高表达与总生存期和无病生存期相关。相比之下,ULBP1的高表达与总生存期改善显著相关,但与无病生存期无关。多个NKG2D配体同时高表达显示出比任何一种NKG2D配体过表达时更好的总生存期和无病生存期。多个NKG2D配体的共表达是生存改善的独立预后指标。此外,多个NKG2D配体的共过表达与NKG2D受体的高表达显著相关。抑制多个NKG2D配体与NKG2D受体之间的相互作用可能是控制EHCC癌症进展和改善患者预后的一种有前景的方法。